Inhibrx Biosciences: The Whole Story Rides On INBRX-106
Inhibrx Biosciences Inc INBX
$82.05
▼ -3.16%
($-2.68)
🔥 High Short Interest
🎈 Low Float
🎢 High Beta
🗓️ Earnings Next Week
Open
$85.63
Prev Close
$84.73
Day Range
$80.35 – $85.63
52W Range
$20.55 – $155.29
Market Cap
$1.20B
Beta
2.93
EPS (TTM)
$-8.39
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-05-28 |
| Shares Out. | 14,670,000 |
| Website | inhibrx.com/ ↗ |
| Phone | 18587954220 |
| Employees | 110 |
| Net Income | -$33.4M |
| Free Cash Flow | -$131.9M |
| Total Assets | $184.0M |
| Total Liabilities | $205.0M |
| Equity | -$21.0M |
About Inhibrx Biosciences Inc
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Inhibrx Biosciences Inc is a publicly traded company under the ticker symbol INBX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-07-01)